Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Carnival's revenues grew 2.7 times in the first quarter

3/27/23 CCL

Acron reported for 2022 according to RAS

3/27/23 AKRN

Yandex intends to make the hub in Serbia the main office for work in the European market

3/27/23 YNDX

Codiak BioSciences filed for voluntary bankruptcy

3/27/23 CDAK

Ministries and Bank of Russia opposed the forced substitution of shares of foreign holdings

3/27/23 MOEX

Sber Eapteca launches online sales of prescription drugs

3/27/23 SBER

Samaraenergo reported for 2022 according to RAS

3/27/23 SAGO

Top managers of Sollers bought 77.6% of the company for ₽4 billion

3/27/23 SVAV

Board of Directors of KuibyshevAzot recommended that dividends be paid for 2022

3/27/23 KAZT

Globaltrans profit in 2022 increased by 65%

3/27/23 GLTR